On Tuesday, Telomir Pharmaceuticals, Inc. TELO revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.

The study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improved oral glucose homeostasis, and reversed insulin resistance to near pre-diabetic levels.

These findings were supported by significantly improved Homeostatic Model Assessment of Insulin Resistance values, a standard measure used to assess insulin sensitivity and resistance.

These effects were also accompanied by increased survival rates in treated subjects.

The company adds that Telomir-1 directly addresses oxidative stress and beta-cell damage by normalizing iron metabolism.

In collaboration with the India-based research organization Pentagrit, Telomir evaluated two forms of Telomir-1, administered orally at three doses, in zebrafish models.

Recently, Telomir Pharmaceuticals’ preclinical results showed that Telomir-1 demonstrates significant age-reversal effects. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decline.

Telomir is advancing additional research, including:

• Progeria (causes rapid aging): Evaluating Telomir-1’s effects on human progeria cell lines and progeria nematode models to investigate its impact on accelerated aging and telomere function and stability.
• Diabetic Mouse Models: Further validating Telomir-1’s efficacy in a mammalian model of Type 2 diabetes.
• Alzheimer’s Disease: Initiating studies to assess Telomir-1’s potential in mitigating cognitive decline and neurodegeneration.
• Osteoarthritis and Inflammatory Diseases: Evaluating Telomir-1’s role in managing joint health and other age-related inflammatory conditions.
• Cancer Models: Exploring Telomir-1’s application in combating age-related oncological conditions.

Price Action: TELO stock is up 15.4% at $4.905 at last check Tuesday.

Read Next:

Image via Shutterstock.